Other News To Note
Friday, October 14, 2011
Sangamo BioSciences Inc., of Richmond, Calif., said a preclinical study demonstrated the highly specific, functional correction of the alpha 1-antitrypsin gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases (ZFN). The study, published in the Oct. 12, 2011, online issue of Nature, highlighted the potential of combining human iPSCs with ZFN-driven gene correction to generate differentiated cell-based therapies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.